Your browser doesn't support javascript.
loading
Development and internal validation of individualized prediction models of overall survival and 6-month mortality among patients with synchronous early-onset colorectal liver metastases.
Chen, Qichen; Li, Kan; Rhodin, Kristen E; Deng, Yiqiao; Lidsky, Michael E; Luo, Sheng; Ding, Peirong.
Afiliação
  • Chen Q; Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Li K; Merck & Co., Inc., Rahway, NJ, USA.
  • Rhodin KE; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Deng Y; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, PR China.
  • Lidsky ME; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Luo S; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
  • Ding P; Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: dingpr@sysucc.org.cn.
HPB (Oxford) ; 2024 Jul 24.
Article em En | MEDLINE | ID: mdl-39122641
ABSTRACT

BACKGROUND:

Early-onset colorectal cancer with synchronous liver metastasis (EO-CRLM) is a growing concern with a grim prognosis.

METHODS:

EO-CRLM patients were identified from the National Cancer Database. Random survival forest model and random forest (RF) model were developed for the prediction of overall survival (OS) and 6-month mortality, respectively.

RESULTS:

The variables with top contributions for random survival forest model of OS included primary tumor resection, chemotherapy and bone metastases. The AUCs of 1-, 3- and 5-year OS were 0.787, 0.763 and 0.761, respectively. The individualized risk profile predicted by the models closely aligned with the actual survival outcomes observed for the patients. The variables with top contributions for RF model for 6-month mortality included chemotherapy, Charlson-Deyo comorbidity score and presence of tumor deposits. RF model for 6-month mortality resulted in an AUC of 0.821 in training set, 0.828 in cross-validation and 0.852 in testing cohort. RF models for OS and 6-month mortality exhibited great net benefit with favorable clinical utility.

CONCLUSION:

The models generated in this study accurately identified EO-CRLM patients at risk of worse OS and short-term mortality, which may complement standard clinical assessment and aid in creation of advanced care planning.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article